Kinnari Patel, Pharm.D., MBA

Kinnari Patel, Pharm.D., MBA

President, Head of R&D and Chief Operating OfficeratRocket Pharmaceuticals· In proxies 2021–2024

Pay in FY2024+38% from the year before · Rocket Pharmaceuticals stock -58.1% the same year

Kinnari Patel, Pharm.D., MBA was paid $6.7M in FY2024 (Dec), up 38%. Rocket Pharmaceuticals stock fell 58.1% that year.

Pay$100 in the stock at the end of FY20 → $23
Pay is from the Summary Compensation Table of each Rocket Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Rocket PharmaceuticalsPublic company · 5 yr
    • President, Head of R&D and Chief Operating Officer2021 – Present · 5 yrStock in role -95%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?